Viral pathogens like Cytomegalovirus (CMV) and Human Papillomavirus (HPV) can affect people across age groups. While the latter can lead to STDs (Sexually Transmitted Diseases), the former attacks a body when it is already immune compromised. For instance, people suffering from HIV are susceptible to an aggression by CMV, the opportunistic pathogen.

In the treatment domain, novelty and improved outcomes will be rewarded over the forecast period of 2014 to 2020.  Surge in demand for CMV and HPV therapeutics is a result of numerous factors – micro and macro.

The global human papillomavirus and cytomegalovirus therapeutics market is set to chart a solid CAGR (Compound Annual Growth Rate) of 7.7% between 2014 and 2020, taking the market worth up to USD 2.34 by the end of 2020, as per a Transparency Market Research study.

It is pertinent to note here that till date, 100+ strains of HPV have been identified. Some of these lead to papillomas and warts. Sometime, lead to cancers – malignant and benign. Also, among young adults and adolescents, it is a common occurrence. And, it goes without saying that HPC infections have a very high prevalence in adolescent females.

In 2012, the United States charted high figures regarding these. Some 20 million people tested positive. 6.2 million new case were expected to emerge each year.

It is also worthy of noting here that the global human papillomavirus and cytomegalovirus therapeutics market is consolidated with Valeant Pharmaceuticals holding a hefty 70% of the market share in HPV Therapeutics, and Roche AG with 85% share – in CMV therapeutics. Other prominent players in the market raising the bar up include Fougera Pharmaceuticals, Perrigo Company plc, Clinigen Group plc and Fresenius Kabi USA.

The only constraint that the global human papillomavirus and cytomegalovirus therapeutics market is facing as of now is a dry therapeutic pipeline. Also, substitutes like cryotherapy are hampering growth. But, this will change with more research and technological advancement in the field.

Immunomodulators to Dominate Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Landscape

The global human papillomavirus and cytomegalovirus therapeutics market consists of sinecatechins, immunomodulators, anti-neoplastic agents, and keratolytic agents when classified by drug class. Out of these immunomodulators and sinecatechins will be largest and fastest growing segments in the market. Among the application segments, genital warts will be most prominent due to sexual contact and increase in it. As more and more young people are getting sexually active, market will grow at an impressive pace. Other divisions in application segment include genital cancer, epidermodysplasia verrucifdormis, oral papillomas and others that contain the likes of Oropharyngeal cancer, laryngeal papillomatosis, etc.

The report by TMR is also segmented by major antiviral drugs for CMV Therapeutics and includes Cidofir, Foscarnet, and Valganciclovir or Ganciclovir. By application, it amcludes sub sections of Encephalitis, Gastrointestinal Ulcers, Pneumonia, CMV Retinitis and others that includes pharyngitis, and mouth ulcers.

Asia Pacific to Generate Lucrative Opportunities of Growth in the Global Human Papillomavirus and Cytomegalovirus Therapeutics Market

The report is regionally segmented into North America, Europe, Asia Pacific, South America, and the Rest of the World.

As healthcare and research infrastructure in the Asia Pacific (APAC) region improves, its contribution to the global human papillomavirus and cytomegalovirus therapeutics market increases. Besides, as economies in the region do well, disposable incomes and thus affordability of treatment options increases. Medical tourism and cultural shift is also leading to growth in the global human papillomavirus and cytomegalovirus therapeutics market.


Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins. The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections. 

The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others). 

Geographically, the HPV and CMV therapeutics market has been categorized into five regions namely, North America, Europe, South America, Asia Pacific, and Rest of the World (ROW). The market size and forecast in terms of USD million for each of these segments has been provided for the period 2012 to 2020, considering 2012 and 2013 as base years. The HPV and CMV therapeutics market report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020.

The report also provides pipeline analysis for HPV and CMV therapeutics market, which includes sales forecast for drug candidates currently under phase III clinical trials, and also mentions other candidates in phase I and phase II trials. The research study explains the competitive scenario in the HPV and CMV therapeutics market through Porter’s Five Forces Analysis. A detailed analysis of various macro as well as micro economic factors driving as well as restraining the growth of this market, in addition to future opportunities, is provided in the market overview section of the report. The report also provides market attractiveness analysis and value chain analysis of the global HPV and CMV therapeutics market. Market share analysis for both HPV and CMV therapeutics market has been included. Furthermore, pricing analysis of therapeutic drugs and costs associated with treatment is also studied in the global HPV and CMV therapeutics market report.

A list of recommendations has been provided to help players establish a strong presence in the market and increase their share. The report also profiles major players in the HPV and CMV therapeutics market on the basis of various attributes such as company overview, financial overview, product portfolio, business strategies and recent developments. Mergers, acquisitions, regulatory approvals and other events have been explained in the company profiles section. Key players profiled in the report include AbbVie, Inc., Actavis plc, Clinigen Group plc, Merck & Co., Inc., Perrigo Company plc, Roche Holdings AG and Valeant Pharmaceuticals International, Inc.

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed the real time market scenario. This primary research represented the bulk of our research efforts, which was further supplemented by extensive secondary research. A bottom-up approach was adopted to arrive at global market shares for 2012 and 2013; while an impact based analysis model was adopted to forecast revenue for each market segment. A review of key players’ product literature, annual reports, and press releases supported the market forecast analysis. The 117 pages global HPV and CMV therapeutics market report describes various market dynamics in 51 figures and charts and 16 tables.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Hpv Cmv Therapeutics Market

Buy Now